LAT-8881 is under clinical development by Lateral Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LAT-8881’s likelihood of approval (LoA) and phase transition for Migraine took place on 31 Mar 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LAT-8881 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LAT-8881 overview

LAT-8881 is under development for the treatment of migraine. The drug candidate is administered through oral and intravenous route. The drug candidate acts on Growth Hormone Receptor (GHR).

It was also under development for obesity, cachexia, sarcopenia, HIV wasting syndrome, neuromuscular disorders, muscular dystrophy, achondroplasia, osteoporosis, joint disease,  neuropathic pain including post herpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), osteoarthritis, lumbar radicular pain, other chronic painful diseases and cartilage repair.

Lateral Pharma overview

Lateral Pharma is a biotechnology company that develops drugs for the treatment of osteoarthritis; and painfull chronic and associated diseases. The company is re-purposing its lead product LAT8881, which is a small amino acid peptide modelled on the C-terminus segment of human growth hormone (hGH). It is investigating LAT8881 in phase 2a, and phase 2b for the treatment of osteoarthritis and various chronic diseases. The company’s LAT8881 has been evaluated using conventional acute and chronic repeat-dose studies in animals. It also has comprehensive preclinical efficacy data capabilities for various disease models, including osteoarthritis. Lateral Pharma is headquartered in Melbourne, Victoria, Australia.

Quick View LAT-8881 LOA Data

Report Segments
  • Innovator
Drug Name
  • LAT-8881
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
  • Sponsor Company: Lateral Pharma
  • Originator: Metabolic Pharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.